Skip to main content
MRK logo
MRK
(NYSE)
Merck & Co., Inc.
$130.48-- (--)
Loading... - Market loading

Merck & Co. (MRK) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Merck & Co., Inc.
MRKNew York Stock ExchangeHealthcareDrug Manufacturers - General

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Stock Details

ExchangeNew York Stock Exchange (NYSE)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone908 740 4000
Address
126 East Lincoln Avenue Rahway, New Jersey 07065 United States

Corporate Identifiers

CIK0000310158
CUSIP58933Y105
ISINUS58933Y1055
EIN22-1918501
SIC2834

Leadership Team & Key Executives

Robert M. Davis J.D.
Chairman, President and Chief Executive Officer
Caroline A. Litchfield
Executive Vice President and Chief Financial Officer
Jennifer L. Zachary J.D.
Executive Vice President and General Counsel
Dr. Dean Y. Li M.D., Ph.D.
Executive Vice President and President of Merck Research Laboratories
Dalton E. Smart III
Senior Vice President of Finance, Principal Accounting Officer and Global Controller
David Michael Williams
Executive Vice President and Chief Information and Digital Officer
Peter Dannenbaum
Vice President of Investor Relations
Chirfi Guindo
Executive Vice President of Strategic Access, Policy and Communications
Betty D. Larson
Executive Vice President and Chief Human Resources Officer
Richard R. DeLuca Jr.
Executive Vice President and President of Merck Animal Health